Trial Profile
Stop imatinib or dasatinib study in CP-CML patients mainitaining complete molecular response for two years
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2013
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms TWMU-TKI-STOP
- 06 Jun 2012 New trial record
- 01 Jun 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.